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We estimated kinetic parameters associated
with methanol disposition in humans from
data reported in the literature. Michaelis-
Menten elimination paramet (Vo 115
mg/Uhr , A- 460 mgIL) we s d for
input into. a.:seimi-physiologic hrci-
ncetic modeLNW.e used reported lira.re Val-
ues for blood or urine Occentra-
tions in humans and nonhuma.primates
after methanol inhalation as input to an
inhalation disp model that evaluated
the absorption ofmethanol, expresed as the
fraction of inhaled methanol. .o.ntration
that was absorbed (0). Values of 0 for
.nonexercising subjects typically vried
between 0ff9.64 -nd 0.75; 0.80 wa Io
to be a reasonable upper boundary for frac-
tional absorption. Absorption efficiency in
exercising subjects was lower than.that in
resting individuals. Incorporaion of the
kinetic and 0P into a plamaco-
kinetic model of human exposriie to
methanol, compared to a similar analysis in
rodents, indicated that following an 8-hr
exposure to 5000 ppm ofm anol vapor,
bloodmanol concentrationsin hemouse
would be 13- to 18-fold ige.r. than in
humans -posex d to the same. m.ethianol
vapor o rion; blood a ol on_-
centrations. in the rat under similar condi-
tions would be 5-fold higher than in
humans. These results demonstrate the
importance in the risk assessment for
methanol of basing extrapolatins. from
rodents to humans on acal bliodcncen-
trations rather than on methanol vapor
exposure concentrations. Key work human-
animal comparison, methanol, physiologo-
cally based ph o netic model, toxico-
kinetics. Environ Health Perspeet 103:
726-733 (1995)
Methanol is awidely used industrial solvent.
Workplace exposures to high methanol
vapor concentrations have resulted in acute
toxicity, including central nervous system
depression and blindness; large oral doses of
methanol have resulted in blindness and
death (1). Investigations ofmethanol inhala-
tion in laboratory rodents have indicated
that high doses ofmethanol cause a variety
ofbirth defects (2-7). As methanol is pro-
posed as a motor fuel additive, the general
public may be exposed to increased levels of
environmental methanol, prompting recent
attempts to assess the risk ofthe teratogenic
potential ofmethanol in humans (8). Alogi-
cal first step in the assessment ofrisk to the
human conceptus, as compared to the
rodent conceptus, is to evaluate the dose of
methanol actually administered to the
mother via inhalation and the time course
of exposure in maternal blood. The dose
administered is not the same as the inhaled
concentration because the inhaled toxicant
may not be absorbed completely. If there
are differences in the absorption ofgaseous
or vapor-phase toxicants between species,
these differences should be considered in
risk assessment. Analyses of the absorption
of water-soluble vapors such as methanol
have suggested that the amount absorbed
varies, and that the benchmark physiologi-
cally-based pharmacokinetic model devel-
oped for inhaled styrene does not provide
accurate predictions of the absorption of
highlywater-soluble substrates (9).
In earlier work in this laboratory (1H,
Perkins et al., submitted), the systemic dis-
position of methanol in female Sprague-
Dawley rats and CD-1 mice was evaluated,
the ventilation in rodents was quantified in
flow-through exposure chambers, and
uptake of methanol vapor from the cham-
ber atmosphere was determined. These data
allowed development ofan inhalation phar-
macokinetic model based on the equation:
dC VC max C
dt ' Vd K +CX
(1)
where Cis the blood methanol concentra-
tion, 0 is the fraction ofinhaled methanol
absorbed into the systemic circulation, Ci
is the ambient methanol vapor concentra-
tion (assuming awell-mixed environment),
Vis the minute ventilation, Vd is the vol-
ume ofdistribution, and Vma, and Km are
the Michaelis-Menten parameters associat-
ed with the maximum velocity ofmetabo-
lism and the concentration atwhich veloci-
ty is one-half maximum, respectively. In
both the rat and mouse, methanol elimina-
tion occurred via apparent Michaelis-
Menten kinetics, with a similar Km
(approximately 50 mg/L) in both rodent
species; VTa, was approximately twice as
large in the mouse as in the rat (154
mg/kg/hr versus 71 mg/kg/hr) (10). The
absorption factor 0 was not constant in
the rat, but varied with both Vand Cinh
(Perkins et al., submitted). Elimination via
the lungs (after exposure) and the kidney is
theoretically a small fraction of total
methanol elimination (8,11) and modeled
well in both rat and mouse without being
specifically included (10). In both the rat
and mouse, the systemic disposition of
methanol was similar after oral (PO),
intravenous (IV), or inhalation administra-
tion (Perkins et al., submitted).
To assess risk to the human conceptus
based on extrapolation from rodent data, it
is desirable to begin with comparisons of
blood methanol concentrations rather than
with the ambient methanol vapor concen-
tration; as demonstrated in rodents, blood
concentrations can vary substantially
between species exposed to the same ambi-
ent methanol concentration. Blood toxi-
cant levels are a more relevant determinant
of systemic effects (such as teratogenicity)
than are ambient environmental toxicant
concentrations (12). The objective of this
study was to apply the inhalation toxicoki-
netic model developed for methanol expo-
sure in rodents to humans, based on blood
methanol data extracted from the litera-
ture. This effort relied on evaluation of
published kinetic parameters after IV or
PO methanol administration to humans
and other primates, estimation of D from
published methanol inhalation studies and
physiological parameters, application of
the model to the data, determination of
which model parameters (if any) required
adjustment to optimize description of the
concentration-time data, and comparison
ofblood methanol concentrations predict-
ed by the human model to observed data
in rodents. In addition, predictions based
on the human model were evaluated for
implications to risk assessment.
Materials and Methods
Because ofthe well-established species dif-
ferences in the acute toxicity of methanol
between primates and nonprimates (1),
the primate is the model ofchoice for both
kinetic and toxicologic studies of
methanol, and only data obtained from
human and nonhuman primates in the
published literature were used in this
study. Numerical values presented in
tables were preferred to values that were
scaled from charts or graphs, although the
majority ofdata were scaled. Many of the
data were reported as methanol concentra-
tions in urine rather than in blood. It has
been shown that blood methanol concen-
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trations are 77% of urine methanol con-
centrations (13); similar values were
reported by other investigators (8,14) and
correspond to earlier work in this laborato-
ry (10). Urine data reported by other
investigators (15-17) were corrected for
specific gravity and/or blood creatinine,
although little advantage was noted in
these corrections. We therefore used
uncorrected urine data.
The general procedure used was to
evaluate systemic kinetic parameters based
on data after PO or IV methanol adminis-
tration, then to fit the inhalation data sets
with Equation 1, maintaining D as the
dependent variable. Data after IV adminis-
tration were modeled with a one-compart-
ment system incorporating saturable elimi-
nation as
dC _C X
dt maxj K +C)I° V m~~~d ~~(2)
where C is the methanol concentration in
the central compartment (18). The initial
condition (C0) is the mass of methanol
administered (X0) divided by the apparent
volume of distribution (V1d). For PO
administration, the model described above
was modified to take into account absorp-
tion ofmethanol from the gut. The rate of
change of blood methanol concentration
after PO administration is
dC [X (Ka)][Vmax C )],
dt Vd Km +C ~~~~~~(3)
where Ka is the first-order rate constant for
absorption from the gastrointestinal tract.
The elimination terms are the same as
Equation 2 above.
At low values of blood methanol, the
saturable elimination in Equation 2
becomes approximately first order:
dC
t =-Kel(C),
where the first-order rate constant Kel is
equal to the ratio of Vma, to Km. Use of
both saturable and linear models facilitates
data acquisition from the literature because
blood concentrations after low-dose
methanol administration frequently are
characterized by the first-order elimination
rate constant or the associated half-life.
One ofthe data sets from the literature
that described high methanol inhalation
exposures of industrial workers displayed
some anomalously high blood methanol
concentrations, which implied that the sub-
jects were eliminating methanol at a much
lower rate than expected. The ethanol co-
administration model was developed to
determine ifrelevant PO doses of ethanol,
co-administered with the methanol inhala-
tion exposure, could account for the anom-
alies. The ethanol co-administration model
assumed direct administration into the cen-
tral compartment, similar to IV dosing, for
simplicity. The model is identical to
Equation 1 butwith two elimination terms,
one for methanol and one for ethanol. The
kinetic parameters used in the model for
ethanol were Vm. = 230 mg/L/hr, Km = 82
mg/L, and Vd = 0.54 L/kg (19). For
methanol elimination, the kinetic parame-
ters are as discussed below, except that Vmax
was modeled as a function of the ratio of
ethanol to methanol in the blood. Based on
earlierworkwhich reported 90% inhibition
ofalcohol dehydrogenase (ADH)-mediated
methanol metabolism when ethanol and
methanol are at equimolar concentrations
and 70% inhibition when ethanol concen-
trations are 25% of methanol concentra-
tions (20), a simple model was developed
that predicted 90% inhibition ofmethanol
metabolism at ethanol concentrations
greater than methanol concentrations, a
linear variation from 70% to 90% inhibi-
tion as the molar ratio increased from 0.25
to 1.0; and a linear increase in inhibition
from 0.0% to 70% as the molar ratio
increased from 0 to 0.25.
Except as noted, the V used was for a
body weight of 70 kg, as reported for
human volunteers in a chamber equipped
with a two-way non-rebreathing valve (21)
or a respirometer (22). This Vis higher
than the estimate of6-7.5 L/min reported
in standard texts (23), but was chosen as
being more representative ofnonexercising
human volunteers in chambers than
humans at rest. Typical Vof 10.3 ± 4.2
L/min were reported for nine human sub-
jects in average classroom and workshop
settings, measured with noninvasive instru-
ments (i.e., no mouthpiece or forced
breathing) (24). The V of 10.5 L/min,
normalized for published bodyweight, also
was used for the nonhuman primates.
The simulations were performed on a
spreadsheet program by converting the dif-
ferentials to finite differences with a time
step of0.1 hr. Where continuous, instanta-
neous values were required (e.g., the blood
concentrations in the Michaelis-Menten
equation), the blood concentration from
the previous time step was used.
Background blood methanol in the human
is approximately 1.0 mg/L from both
endogenous and exogenous sources (8),
and this level was used for the initial time
step. Studies based on 0.01-hr time steps
indicated no significant loss ofaccuracy by
use ofthe larger time step. Nonlinear least-
squares regression, where required, was
performed with PCNONLIN (Statistical
Consultants, Inc., Lexington, Kentucky).
Results
Several investigators have reported a KR for
methanol of approximately 0.25 hr' (25)
or 0.23-0.28 hrf1 (1) in humans. Other
investigators, however, reported a Kel of
0.101 hrii for oral doses of3, 5, or 7 mL of
methanol (13). Those authors assumed that
100% of the dose was absorbed within 1
hr, and they did not otherwise account for
absorption ofmethanol from the gut. Their
methanol blood concentration-time data
were fit with the one-compartment model
with first-order absorption (Equation 3) by
nonlinear regression, which yielded a K =
0.25 hrf, aKa= 2.15 hrf, and a Vd = 0.84
L/kg. The estimates ofboth and Vdwere
similar to corresponding constants in the
mouse and rat [Ka = 2.1 1 for rats, and 2.98
for mice (average of fast and slow absorp-
tion processes); Vd = 0.85 for rats and 0.76
for mice] determined previously in this lab-
oratory (10).
In previous investigations, a Lineweaver-
Burke plot based on methanol doses in the
rhesus monkey 0.05-1.0 g/kg (producing
blood methanol concentrations of approxi-
mately60 to 1200 mg/L) was used to recov-
er an apparent Km of 278 mg/L, based on
Vdof0.7 L/kg (20). In otherwork, a Km of
544 mg/L for methanol was reported with
the monkey ADH enzyme in vitro (26).
Still other investigators estimated the Km for
ethanol in humans and assumed, based on
the much weaker binding of methanol to
ADH, that the Km for methanol should be
640 mg/L (27). Based on the average of
these estimates (460 mg/L) and a Aelof0.25
hrf1, VMax was estimated for this investiga-
tion to be 115 mg/L/hr.
Nonlinear regression analysis of avail-
able data is presented in Table 1. The range
of Km estimates was between 252 and 716
mg/L, with a mean of484 mg/L (similar to
the average value of 460 mg/L noted
above). Since the monkey is a good model
for human methanol metabolism, Km,
which is a function of enzyme binding,
should be approximately the same between
primate species and genetically and envi-
ronmentally diverse humans. Vmax is
expected to vary at least somewhat between
individuals and species due to differences in
the total amount of enzyme. A Km of 460
mg/L was selected and used in Equation 3
to calculate the concomitant Vmax of 115
mg/L/hr, which was incorporated into all
modeling except as noted. Figure 1 shows
the fit of Equation 2, incorporating those
values of Vmax and Km to data sets obtained
from the literature (28-30). The reasonable
correspondence between model estimates
and observed data suggested that the para-
meter values estimated above were suitable
for further evaluations.
The model (Equation 1) was used to
determine the value of(I that provided the
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best fit ofthe available data. That is, () was
evaluated as the dependent variable using
the exposure concentration as the indepen-
dent variable and V,V.., and K. as
known parameters for each value ofCjh in
the data sets. Data obtained during inhala-
tion exposures were divided into three
groups: low dose (50-300 ppm), mid-dose
(500-2000 ppm), and high dose (>2000
ppm) for modeling purposes.
Low dose. Groups of three or four
healthy humans were exposed for 8 hr to
environments of 77, 156.5, and 229 ppm
methanol in air, and urine methanol con-
centrations were determined (22). Figure 2
shows the estimated blood methanol con-
centrations in those subjects and model
predictions with the parameters defined
above and (D = 0.645; thatvalue of( yield-
ed exactly the 8-hr blood methanol concen-
tration of the 156.5 ppm dose. Those
authors also reported a "retention factor,"
which is equivalent to a 4D of57.7%. This
factor was deduced by having the subjects,
who had their noses clipped shut, breathe
through a two-way valve; the difference
between inhaled and exhaled methanol
concentrations was then measured.
Other investigators (21) exposed four
subjects to 200 ppm methanol, the current
allowable exposure threshold limit value
(TLV) for workers (31). Two different
experiments measured subjects either at
rest or during exercise. Ventilation was
measured with a two-way non-rebreathing
valve. These data are reproduced in Table
2, alongwith the e that was required to fit
the methanol inhalation model to these
data. Although the difference in blood
methanol concentrations at 6 hr between
the exercise and resting groups was not
statistically significant, the computed 1
indicated that fractional methanol absorp-
tion was much lower in the exercise group.
Mid-dose. Individual subjects were
exposed to approximately 500 and 1000
ppm methanol for relatively short durations
(approximately 2-5 hr) (13). The observed
blood methanol concentrations are com-
pared to model predictions in Figure 3. A
different value of e was required to fit the
data for each subject. The data from one
subject, who weighed 57 kg, required eD =
0.79; the other subject, who weighed 78.5
kg, required 4) = 0.67-0.70.
Other investigators (32) exposed groups
of 4 male rhesus monkeys to 50, 200,
1200, or 2000 ppm methanol for 6 hr and
reported the resulting blood concentration
at the end of exposure and for the subse-
quent 18 hr. No increase in blood
methanol concentration for the 50 ppm
group was reported, and concentrations in
the 200 ppm group were close to back-
ground and therefore difficult to interpret.
For the 1200 and 2000 ppm exposures, the
methanol inhalation model estimated a 4 to high methanol vapor concentrations (up
of0.69 (data not shown). to 5000 ppm), yielding very high blood
High dose. Several articles (15-17) pre- methanol concentrations (>250 mg/L).
sented the results ofexaminations ofwork- Those investigators provided linear regres-
ers in Japan, some ofwhom were exposed sion analysis of blood or urine methanol
Table 1. Nonlinear least-squares regression analysis of four methanol oral or intraperitoneal exposures
(means ± SE)
Vmax Km Dose, species Reference
132 ± 36 716 ± 489 2 g/kg, cynomolgus monkey (29)
93 ± 87 320 ± 1273 1400 mg/L humana (28)
48 278 Various doses, rhesus monkeyb (20)
59±7 252±116 1 g/kg,cynomolgusmonkey (30)
aBlood methanol concentration shortly after admission to hospital.
bDoses of0.05-1.0mg/kg given; Vmax and Km reported, based on analysis of Lineweaver-Burke plot.
*Human (281
a Cynomolgusmonkey1328
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Figure 1. Demonstration of one-compartment model with Michaelis-Menten elimination (Eq. 2), with Vmax
= 115 mg/kg/hr and Km = 460 mg/L (lines) to the data (symbols) for humans (28) and cynomolgus monkeys
(29,30). C0 calculated by dose/Vdif dose was given, or calculated by regression.
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Figure 2. Demonstration of methanol inhalation model (Eq. 1) using 4 = 0.645 (lines) to the low-exposure
data (symbols) (22).
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Table Z Summary of absorption factor,4), deduced from reported human data and measured in rodent
experiments
Cinh(ppm) 4) Notes Reference
Low exposure
77-229 0.645 V= 10.5 L/min, measured (21)
200 0.740 V= 10.5 L/min, measured (22)
200 (exercise) 0.50 V= 18.6 L/min, measured
Medium exposure
500-1000 0.79 57 kg subject (13)
0.67-0.70 78.5 kg subject
Mouse
2500 0.86 ± 0.19 (Perkins et al.,
submitted)
10,000 0.83 ± 0.12
Rat
2500 0.88 ±0.16 (Perkins etal.,
submitted)
10,000 0.70 ± 0.07
0 1 2 3
lime(hr)
Figure 3. Demonstration of methanol inhalation model (Eq. 1) to the mid-exposure data (13). Data from
similar experiments were combined (i.e., a 500 ppm and 559 ppm experiment were combined into their
approximate average of 525 ppm for the plot). Lines are the model predictions, symbols are the actual
data points.
concentration at the end of an 8-hr shift
versus the exposure concentration (Fig. 4).
The blood methanol concentrations pre-
dicted by the inhalation model were much
lower than the observed data; at a (D of 1.0,
the model underpredicted the data by25%.
Since the authors described the workplace
where the samples were taken and gave no
indication of heavy exercise or labor that
would increase V significantly, the only
variables in Equation 1 that are likely to
account for the underprediction are in the
elimination term. Eight workers studied
demonstrated a definite anomaly in their
blood methanol concentration-time pro-
file. First, the workers' blood methanol at
the beginning of a shift (BOS) averaged 22
mg/L, compared with the 1 mg/L average
in nonexposed humans (an upper 95%
confidence limit on 72 unexposed controls
was 3.63 mg/L). Second, after a methanol
exposure of 1288 ppm methanol (geomet-
ric mean) for 8 hr, the average end-of-shift
(EOS) blood methanol concentration for
these workers was 144 mg/L. Employing
the kinetic parameters for elimination
described above, blood methanol should
have returned to background (1 mg/L)
within 10.7 hr.
These data were reanalyzed from two
perspectives for modeling purposes. First,
because the data were gathered late in the
work week, it was assumed that the EOS
blood concentrations shown were the same
as the EOS concentrations the day before
(i.e., steady-state conditions prevailed); the
VMax that would be required to yield the
BOS blood methanol concentrations
observed on the following day were calcu-
lated. The Vm. calculated in this manner
for each ofthe eight workers averaged 63 ±
13.8 mg/L/hr. The second approach was to
Table 3. Blood methanol concentrations after an
8-hr exposureto methanol vapor
Methanol Blood methanol concentrations (mg/L)
(ppm) Mouseb RatC Humand
100 4-5 5.5 4
200 9-12 11 7.5e
305 15-20 17 11.5
500 29-45 31 19f
1000 132-268 93.5 38.5f
3078 1585-2315 558 129
5000 2976-4188 1018 2249
8The 1000 and 5000 ppm rat and mouse data are
computed for environmental exposures, but
closely correspond to data from actual chamber
exposures (Perkins et al., manuscripts submitted).
All other data represent computed values.
bRange indicates two different ventilation pat-
terns observed; low number represents slow
breathers, high number represents fast breathers
(Perkins etal., submitted).
cV as a function of blood methanol and 4) as a
function of Cinh is accounted for in the rat model
(Perkins et al., submitted).
Based on 4) = 0.75.
eApproximately actual (Fig.2).
fApproximately actual up to 4 hr (Fig. 3).
gField work indicates 411 mg/L for 8-hr exposure
to this methanol vapor concentration (see text
regarding high exposures).
use the standard inhalation model (with
normal ventilation and D = 0.75), but
starting at time 0 with the actual average
worker BOS blood methanol of 22 mg/L.
The Vmax required to yield the EOS blood
concentrations then was calculated. This
analysis yielded a Vm. of 44 mg/L/hr for
the average worker.
Discussion
The kinetic modeling at low- and mid-
doses of methanol vapor in humans sup-
ports earlier findings in this laboratory in
the rat and mouse: there is little, if any,
difference in methanol disposition during
and after methanol inhalation as compared
to that after PO or IV administration. The
model accurately predicted the decline in
methanol blood concentration following
removal ofthe monkey (32) or the human
(22) from the methanol exposure environ-
ment. Because the model used Vm. and
Km estimates based on PO and IVadminis-
tration, the kinetic constants must have
been similar after inhalation.
The one-compartment methanol
inhalation model with Michaelis-Menten
elimination accurately predicted blood
methanol concentrations after low and
moderate doses of methanol vapor up to
1000 ppm [i.e., fivefold higher than the
current TLV and also about fivefold higher
than the maximum environmental expo-
sure expected from the use ofmethanol in
automobile fuel (8)]. The absorption factor
(4) for nonexercising subjects varied
Volume 103, Number 7-8, July-August 1995
25
20
15
10
a E
0
S M
0
72980
0
0 1 2 3 4 S
lime (hr)
Figure 4. Comparison of the high-exposure methanol inhalation model (Eq. 1) to the data of methanol-
exposed Japanese workers (15-17). The green line is a linear regression plot of urine converted to blood
methanol by the factor of 0.77 (urine concentration) = blood concentration.
between 0.65 and 0.75, except for one sub-
ject, a 57-kg adult male, where a (D of0.79
best described the data. A of 0.80 may
be an appropriate upper bound for frac-
tional methanol absorption in humans,
with a 4D of 0.65-0.75 representing the
usual range; the model based on a D of
0.75 accurately predicted all the low- and
medium-dose data. Previous work demon-
strated that, for exercising subjects with a
ventilation 77% above resting, decreased
to about 0.50 (21). This decrease in 4D
with increasing ventilation is supported by
measurements with a two-way valve (22, a
device that forces 100% mouth breathing
and presumably increases ventilation some-
what; the resulting 'D was 0.57, which was
less than the (I calculated for nonexercis-
ing subjects in that study.
Earlier work in this laboratorywith rats
suggested a decrease in (D with increased
ventilation (Perkins et al., submitted), but
this effect was not well reproduced in rats
with ventilation artificially increased by
carbon dioxide loading (Perkins et al., sub-
mitted). Rats demonstrated a significant
decrease in (D with increasing inhalation
concentrations up to 20,000 ppm; this
decrease was not apparent in humans at
the low and medium vapor concentrations
(up to 2000 ppm; Table 2). This lack of
effect of exposure concentration on tD in
humans may be a consequence ofthe rela-
tively low exposure concentrations.
Alternatively, methanol in the humans
may behave more like it does in the mice
than in rats; in mice also was indepen-
dent of exposure concentration (Perkins et
al., submitted).
Some discussion of the decrease in
between species with increasing body size
(Table 2) is warranted. The high blood:air
partitioning of water-soluble vapors pre-
dicts that such substrates should be
absorbed completely upon inhalation. The
most likely explanation of the less than
100% absorption ofthese substances (9) is
the concept of "wash-in, wash-out" (33).
During inhalation, 100% of the inhaled
water-soluble vapor is adsorbed on the lin-
ing of the upper respiratory tract (URT),
and this adsorbed vapor diffuses away from
the mucous lining toward the capillary
blood. The diffusion process is relatively
rapid but not instantaneous, so that the
mucus lining still contains residual sub-
strate when the exhaled air, devoid ofsub-
strate at the start of exhalation, re-entrains
some residual substrate from the URT lin-
ing. The decrease in with increasing
species size is paradoxical because the larger
species breathe at a lower frequency (120,
70, and 15 breaths/min for the mouse, rat,
and human, respectively). The lower
breathing frequencywould allow more time
for the diffusion ofthe vapor away from the
URT lining before start of exhalation,
hence the fractional absorption should be
higher in a slower-breathing species. One
explanation for this apparent anomaly is
that, normalized for body weight, the
smaller species' URT must clean, warm,
and humidify larger volumes of air (1.51,
0.52, and 0.15 L/min/kg in the mouse, rat,
and human, respectively) in a shorter linear
distance between nares and lungs. The bio-
logical requirements for more rapid heat
and water vapor mass transfer in the smaller
species may be a more important factor
favoring overall mass transfer than the
increased time for diffusion in the slower
breathing, larger species.
Table 3 illustrates two factors that are,
in general, important for extrapolations
used in methanol risk assessment. First, the
increased ventilation per unit body weight
associated with the smaller species leads to
increasingly larger differences in the blood
concentrations as inhaled vapor concentra-
tion increases. Ventilation per kilogram is
10-fold and 3.5-fold larger in mice and
rats, respectively, than in humans; this dif-
ference is magnified because D in humans
is lower than in rodents. The differences in
blood methanol concentrations between
species, however, are not that large, espe-
cially at lower exposure concentrations
(<1000 ppm), highlighting the importance
of an understanding of systemic kinetics:
while the Vm. for methanol elimination is
approximately comparable for the three
species (120, 60, 96.6 mg/kg/hr in the
mouse, rat, and human respectively), the
Km differed by an order of magnitude
(approximately 50 mg/L in rodents versus
460 mg/L in humans). After an 8-hr expo-
sure at 1000 ppm, for example, the rodents
metabolized methanol at 70-87% of V max
(i.e., approaching saturation), while the
human metabolized at about 8% ofVm..
The high-dose data from the methanol-
exposed Japanese workers (15-17) also
raises questions regarding the use of the
model for risk assessment. Using the model
parameters that yielded a good fit of the
low- and mid-dose datawould substantially
underpredict the high-dose data presented
by these authors. The parameter values that
would result in a better model fit were con-
sidered. The underprediction likely was not
due to an underestimate of V in the model:
because the subjects were not exposed to
heavy exercise, the value of V used in the
model was approximately 25% higher than
the "at rest" estimates published in physiol-
ogy texts (23) and slightly higher than that
V reported for a mixture oflight activities
(24). Moreover, an underprediction ofCI is
unlikely to be responsible for the underpre-
diction of blood methanol concentrations.
In rodents, an increase in inhaled methanol
concentration resulted in a decrease in 4D
(Perkins et al., submitted). The value of (D
used in the model (0.75) washigher than the
mid-range ofvalues calculated for humans
(Table 2). In addition, a theoretical maxi-
mum 1 of 1.0 still underpredicted concen-
trations by about 25%. While the kinetic
parameter Vdcould decrease with decreased
cardiac output due to central nervous system
(CNS) depression, clinical examination of
the workers did not reveal CNS depression,
norwould a decrease in volume likely have a
large effect on methanol concentrations
because the alcohol diffuses rapidly through-
out thebodywater.
Variations in the elimination parame-
ters provide the most likely explanation for
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blood methanol concentrations during and after methanol exposure assuming BOS blood methanol con-
centrations accumulated over 4 consecutive days (typical "Friday" exposures) after 30-mL doses of pure
ethanol atthe indicated times. (A) 1000 ppm methanol; (B) 200 ppm;(C) 5000ppm.
these data. Km is a function of the ADH
enzyme system, which is assumed to be
similar in all primates. Vmax, therefore, is
the parameter most likely to be the cause
of the relatively slow elimination observed
in this study. In order for the model
(Equation 1) to be accurate, Vmax must be
reduced to less than half the value used at
lower exposures. The Vmax and Km (115
mg/kg/hr, and 460 mg/L) used in the
modeling were chosen based on literature
values of K and t1/2, which are frequently
reported and can be measured accurately,
and an average value of Km reported for
primates. Table 1 shows VKn and Km cal-
culated by nonlinear regression directly for
primate data sets, without regard to the
relationship between Kel Vmax, and Km
(Eq. 4). Some ofthe V1ax values in Table
1 are much lower than the Vma. used in
the model, but these were associated with a
correspondingly low Kin; the net result is
about the same. For example, after a 4000
ppm exposure for 8 hr, the reported rela-
tionship (16) predicts blood methanol con-
centrations of 315 mg/L, whereas the
model using the standard Vmax predicts
174 mg/L. Using the lowest three values of
Vma. in Table 1 with the corresponding
Km predicted EOS blood methanol con-
centrations were 168, 228, and 201 mg/L.
These values still represent substantial
underpredictions. Hence, variation in Vmax
with a constant Km was considered as the
likely cause ofthe underprediction.
One possible explanation of these
apparently anomalous results is that the
workers were co-exposed to chemicals that
inhibited ADH or otherwise affected
methanol elimination. The authors did not
note any such co-exposures. Another possi-
ble cause of variations in Vmax would be
that the Japanese workers tested were
genetically different from Caucasian sub-
jects used in other studies. Variants of
ADH and aldehyde dehydrogenase
(ALDH), the principal metabolic enzymes
responsible for the metabolism of
methanol in primates, are well known in
various populations, including the
Japanese (27,34). Ifthis were the case for
susceptible workers exposed to methanol
vapors, the implications for risk assessment
are obvious. A worker exposed for 8 hr at
the current TLV (200 ppm) with a Vm. of
11.5 mg/L/hr (10% of normal Vmax)
would experience a BOS concentration the
following day of 10.8 mg/L (10 times nor-
mal background), which should be easily
detected in blood or urine samples.
Another explanation for the anom-
alous high blood concentrations would be
the co-administration of ethanol. All the
other data sets described in this paper were
gathered from controlled groups, animals,
or volunteers. Ethanol is a significant
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inhibitor of methanol elimination in pri-
mates, due to the higher affinity of
ethanol for the ADH enzyme. Equimolar
concentrations of ethanol and methanol
yield a Vmax for methanol elimination of
about 10% of the Vm. in the absence of
ethanol; even a 0.25 molar ratio (ethanol
to methanol) reduced VKn to 30% ofnor-
mal (20). Indeed, this inhibition has been
used for treatment ofacute methanol toxi-
city, since ethanol slows the conversion of
methanol to formate (1). Furthermore,
this inhibition is significant at relatively
low doses of ethanol. The current recom-
mended blood concentration ofethanol to
treat methanol toxicity is 1000 mg/L (27)
or 500 mg/L (1), which approximates
intoxicating concentrations following alco-
hol consumption (800 mg/L is the defini-
tion oflegal impairment for motor vehicle
operators in North Carolina). Methanol
elimination may be significantly inhibited
in an intoxicated worker without affecting
job performance. While the inhibition of
methanol elimination by ethanol at rela-
tively low doses is clear, ethanol also is
eliminated rather rapidly from the body
(Ke, for low doses of ethanol is 10 times
higher than Ke, for methanol). The
ethanol co-administration model was
developed to examine the relationship
between ethanol and methanol regarding
inhalation exposure, both as a possible
explanation of the high-dose data and for
general application in risk assessment. The
ethanol co-administration model was
based on elimination of ethanol at a con-
stant Vmax and methanol at a variable Vm.
as described above. V and D were 10.5
L/min and 0.75, respectively. Figure 5A
presents a model of blood methanol and
ethanol compared to methanol alone. The
model assumes doses of 30 mL pure
ethanol at 0, 4, 8, 12, and 16 hr, and a
methanol exposure of 1000 ppm between
0 and 8 hr, for two cases. One case
assumes initial BOS blood methanol is
unexposed background; the second case
adjusts the BOS methanol for each of the
preceding 4 days to allow for methanol
cumulation; the Monday and Friday 8-hr
blood methanol concentrations are 75%
to 100% higher than the model predic-
tions without ethanol co-administration.
Figure 5B and C demonstrate the same
ethanol regimen, with a 200 and 5000
ppm methanol exposure. The 200 ppm
exposure shown in Figure 5B indicates
that the 8-hr blood methanol concentra-
tions predicted are approximately two-fold
greater in the ethanol co-administration
predictions, but are still low (less than 20
mg/L maximum) and return to approxi-
mately background each day. The SOOO
ppm exposure with ethanol co-administra-
tion predictions shown in Figure SC are
42% and 62% higher than without the
co-administration. The 8-hr 5000 ppm
exposure with ethanol co-administration
estimation (321-365 mg/L) approaches
the 394 mg/L predicted for that exposure
(16).
The model developed (without ethanol
co-administration, genetic deficiencies in
ADH/ALDH, or other factors that reduce
methanol metabolism) does not consider
directly the time course of formate (the
major metabolite of methanol), and it
remains unclear whether it is the parent
compound or the metabolite, or some
combination ofthe two, which is responsi-
ble for the observed teratogenicity of
methanol in laboratory rodents. In any
case, the kinetics of the metabolite follow
directly from the model, once the transfer
of parent from the air into the blood is
known. The present model provides that
capability, and also illustrates some inter-
esting concepts regarding inhalation toxi-
cology. Consider Table 3, using the pro-
posed benchmark dose of 3078 ppm in
the mouse for a 5% added risk of either
exencephaly, cleft palate, or fetal resorp-
tion (4). Applying a safety factor of 10 to
the inhaled concentration for extrapola-
tion between the mouse and the human
indicates that a maximum allowable expo-
sure concentration of 308 ppm would be
required to protect humans from
methanol teratogenicity. If one were to
base the factor ofsafety on the blood con-
centration, Table 3 indicates that, for a
3078 ppm methanol vapor exposure, mice
experience 12- to 18-fold higher blood
methanol concentrations than humans.
Thus, humans would already have a factor
ofsafety of 13 to 18 at the same exposure
concentration. However, considering the
proposed benchmark dose for a 5% added
risk of cervical rib defects in mice of 305
ppm, and assuming the same 10-fold safe-
ty factor, a maximal allowable exposure
concentration of about 30 ppm would be
required. This would be about the same as
if the extrapolation were based on blood
concentrations. It should also be noted
that, after an 8-hr exposure at the current
TLV (200 ppm), the blood methanol con-
centrations in mice, rats, and humans are
approximately the same. The model
process and data presented here demon-
strate the need to base risk assessment
extrapolations between species on actual
blood concentrations of the xenobiotic
due to the inhalation rather than on envi-
ronmental vapor concentrations.
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